Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Share

📰 source: cnbc_topnews · 💼 business

eli lilly crushed wall street's second-quarter expectations on wednesday, posting adjusted earnings of $8.38 per share on revenue of $22.97 billion, versus the $6.01 and $20.73 billion analysts had predicted. the company raised its full-year revenue outlook to $85-87 billion and adjusted profit to $35.50-36.50 per share, though that includes $3.03 in deal charges. shares rose over 5% in premarket trading.

mounjaro worldwide revenue jumped 91% to $9.94 billion, with international sales up 172%. zepbound brought in $4.93 billion in u.s. revenue, up 44%. the new oral pill foundayo pulled in $98 million. lilly is on a spending spree, buying a psychedelics drugmaker in july and three vaccine makers in may.

revenue outside the u.s. soared 80% to $8.6 billion, lifted by volume growth. ceo dave ricks expects global glp-1 use to rise from 20 million patients to 30 million by end of 2026. medicare's new obesity drug coverage, which began in july, should help both lilly and novo nordisk in the second half.


why it matters: lilly's blockbuster glp-1 sales beat shows obesity drug demand is still exploding, pressuring competitors and suppliers.


source: cnbc_topnews
sentiment: +0.70 · impact: 0.80

Read more